Change of https://www.gov.uk/government/publications/ganaxolone-acmd-advice

Change description : 2026-02-23 12:00:00: Added link to government response. [News and communications]

Showing diff : 2025-08-13 14:02:15.181462400 +00:00..2026-02-23 12:02:07.138363537 +00:00

Correspondence

Ganaxolone: ACMD advice

Letter from the Advisory Council on the Misuse of Drugs (ACMD) to the Minister for Policing and Crime Prevention, about the classificationconsideration of ganaxolone.

From:
Advisory Council on the Misuse of Drugs
Published
13 August 2025
Last updated
23 February 2026 — See all updates

Documents

ACMD advice on ganaxolone (accessible)

HTML

ACMD advice on ganaxolone

PDF, 107 KB, 3 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

Ganaxolone is approved for marketing in the UK for the treatment of CDKL5, a rare epileptic seizure disorder. This letter provides advice on whether ganaxolone warrants control under the Misuse of Drugs Act 1971.

Read the government response to the 3 ACMD reports on medicines.

Updates to this page

Published 13 August 2025
Last updated 23 February 2026 href="#full-history">+ show all updates

  1. Added link to government response.

  2. First published.

Sign up for emails or print this page

Update history

2026-02-23 12:00
Added link to government response.

2025-08-13 15:00
First published.